Association of cochlin-tomoprotein levels with hearing outcomes and initial symptoms in patients with suspected perilymphatic fistula

Le résumé fourni par la source

Background Cochlin-tomoprotein (CTP) has recently emerged as a promising diagnostic marker for perilymphatic fistula (PLF), but its utility beyond diagnosis remains unclear.Aims/Objectives We aim to clarify whether CTP levels could help to predict prognosis, treatment efficacy and initial symptoms for PLF.Material/Methods This retrospective study included 20 patients with acute sensorineural hearing loss who underwent CTP testing.Results Among cases of PLF (CTP levels ≥30 ng/mL), higher CTP levels were significantly associated with poorer improvement of hearing. However, the patients with PLF showed better improvement of hearing than those without PLF. When using a level of CTP <25 ng/mL, the surgical intervention group showed better improvement of hearing than the conservative treatment group. The patients presenting progression of hearing loss (≥10 dB) showed significantly higher levels of CTP. Receiver operating characteristic curve analysis revealed that a cut-off level of CTP 26.9 ng/mL predicted hearing improvement ≥15 dB with an AUC of 0.85 (95% CI: 0.68–1.00, p = 0.0335), yielding a sensitivity of 68.8% and a specificity of 100%.Conclusion The current proposal of CTP ≥30 ng/mL or nearby levels can be used not only as a diagnostic marker, but also as an indicator for initial symptoms and prognosis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.